Blog

Merck hails rise in patient tests for immunotherapy drug Keytruda – Financial Times


Financial Times

Merck hails rise in patient tests for immunotherapy drug Keytruda
Financial Times
Merck recently became the first company to win regulatory approval to also use the drugs to treat some lung cancer sufferers that have not yet tried chemotherapy, giving it an edge in a three-way battle with rival immunotherapy makers Bristol-Myers
Merck unveils new Keytruda DTC adBioPharma Dive


Merck 2017 forecast reassuring; full-speed ahead with KeytrudaReuters
Merck revenue declines as generics weighMarketWatch

all 30 news articles »

2017-02-02 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.